


UPDATE Aducanumab: Potential Monoclonal Antibody Therapy from Biogen



Aducanumab is a monoclonal antibody currently under FDA review for treatment in early Alzheimer's Disease. This medication is delivered via infusion and targets brain amyloid

by using an individual's immune system to reduce levels of amyloid in the brain. The KU Alzheimer's Disease Center (KU ADC) has been a site for testing this new medication, with some patients continuing to receive the study drug today.

The FDA was set to announce its decision on approval in March 2021, but this was recently postponed to June 2021. It is unclear whether the FDA will approve this medication or

not, as a panel of experts in November 2020 voted that the study data was not convincing enough to support approval of the medication. Regardless of the final outcome, this is an exciting time in Alzheimer's research as it has been over 18 years since a medication was approved to treat Alzheimer's disease. Dr. Jeffrey Burns, co-director of the KU ADC, feels that even if this medication is not approved, this is a sign that more medications to treat Alzheimer's disease will be considered for approval.

WHAT IS THE COGNITIVE CARE NETWORK (CCN)?

An ADC partnership program to advance early detection and patient empowerment through education and navigator support to providers, patients, and care partners who are experiencing a cognitive impairment.

REFERRING TO RESEARCH AT THE KU ADC::

We have studies for patients with:

- Normal Cognition
- Mild Cognitive Impairment
- Alzheimer's Disease
- Frontotemporal Dementia

KU HEALTH SYSTEM PROVIDERS

EPIC O2 REFERRAL CODE **REF242**
AMB REFERRAL TO
ALZHEIMER RESEARCH

NON-KU HEALTH SYSTEM PROVIDERS

PHONE **913.588.0555** OPT 1
FAX **913.574.0979**
EMAIL **KUADC@KUMC.EDU**

Questions about research, study information or materials, contact: **KELSEY STRUBE** Provider Engagement Coordinator
913.588.4188 | KSTRUBE@KUMC.EDU

We are a comprehensive Alzheimer's Disease Center located in Fairway, KS, with programs that include research, social work support, and direct clinical care. We have many groundbreaking research opportunities at the KU Alzheimer's Disease Center.

INVESTIGATOR SPOTLIGHT:: DR. JEFFREY BURNS

MEDICAL EDUCATION / University of Kansas School of Medicine

RESIDENCY / University of Virginia

FELLOWSHIP / Alzheimer's Disease Research Center at Washington University in St. Louis

MASTER'S OF SCIENCE / MS in Clinical Research at the University of Kansas



RESEARCH INTERESTS /

- Supporting clinical trials testing new approaches to treating Alzheimer's Disease (AD)
- Research programs focused on lifestyle changes, such as diet and exercise to prevent or delay the onset of AD
- One of the studies Dr. Burns is the Principal Investigator (PI) for is the Dapagliflozin or DAPA Study

STUDY SPOTLIGHT / DAPAGLIFLOZIN IN ALZHEIMER'S DISEASE

Short-term study testing the effect of Dapagliflozin (Farxiga) on brain energy levels and cognitive function in participants with Mild Cognitive Impairment (MCI) or Alzheimer's Disease (AD). The medication is given as a daily 10mg tablet for 12 weeks to monitor its effects on metabolism, and cognitive function.

Your patients may qualify for the DAPA study if they are:

- 60-85 years old
- Have a diagnosis or MCI or AD
- Have a study partner